Add BrightSurf on Google Email

Science News for October 9, 2010


Budget constraints limit FDA inspections

Research reveals that budgetary constraints have led to a less rigorous FDA inspection process, failing to provide necessary oversight and guidance to the pharmaceutical manufacturing industry. This can result in manufacturers taking advantage of the system and prioritizing complaints over addressing actual safety issues.

SourceInderscience Publishers·JournalInternational Journal of Business Continuity and Risk Management·DateOct 9, 2010

Erlotinib improves progression-free survival as first-line therapy in advanced lung cancer

Erlotinib has been shown to improve progression-free survival in patients with advanced lung cancer carrying EGFR activating mutations. The OPTIMAL trial found that erlotinib nearly tripled progression-free survival compared to a standard chemotherapy combination. Safety analyses also showed lower rates of adverse events with erlotinib.

SourceEuropean Society for Medical Oncology·JournalAnnals of Oncology·DateOct 9, 2010

Health halos that make us fat

Researchers found that individuals who dine at establishments labeled as healthy tend to underestimate their actual caloric consumption and subsequently indulge in high-calorie treats. To combat this effect, experts suggest doubling estimated calorie counts for meals served at these restaurants.

SourceCornell Food & Brand Lab·JournalJournal of Consumer Research·DateOct 9, 2010

Investigational ovarian cancer drug shows promise against platinum resistant disease

A Phase II clinical trial of MLN8237, a selective Aurora A kinase inhibitor, demonstrates single-agent activity with durable disease control in some patients with ovarian cancer resistant to platinum-based chemotherapy. The study found encouraging responses in several patients, suggesting potential for future combination therapies.

SourceEuropean Society for Medical Oncology·JournalAnnals of Oncology·DateOct 9, 2010